AACR
MRK icon

ACR Alpine Capital Research’s Merck MRK Stock Holding History

ACR Alpine Capital Research’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75M Buy
39,449
+2,553
+7% +$295K 0.07% 26
2025
Q4 		$3.88M Buy
36,896
+757
+2% +$71.1K 0.06% 29
2025
Q3 		$3.03M Buy
36,139
+2,317
+7% +$191K 0.05% 28
2025
Q2 		$2.68M Buy
33,822
+696
+2% +$55.3K 0.05% 28
2025
Q1 		$2.97M Buy
33,126
+5,587
+20% +$522K 0.06% 26
2024
Q4 		$2.74M Buy
27,539
+11,914
+76% +$1.23M 0.06% 27
2024
Q3 		$1.77M Buy
15,625
+3,111
+25% +$370K 0.05% 30
2024
Q2 		$1.55M Sell
12,514
-5,219
-29% -$672K 0.05% 28
2024
Q1 		$2.34M Buy
17,733
+726
+4% +$89.5K 0.07% 27
2023
Q4 		$1.85M Buy
17,007
+2,240
+15% +$233K 0.06% 28
2023
Q3 		$1.52M Hold
14,767
– – 0.06% 27
2023
Q2 		$1.7M Buy
14,767
+4
+0% +$454 0.06% 25
2023
Q1 		$1.57M Sell
14,763
-8
-0.1% -$864 0.06% 25
2022
Q4 		$1.64M Sell
14,771
-1,916
-11% -$196K 0.07% 26
2022
Q3 		$1.44M Buy
16,687
+1,818
+12% +$162K 0.07% 26
2022
Q2 		$1.36M Buy
14,869
+77
+0.5% +$6.83K 0.06% 27
2022
Q1 		$1.21M Buy
+14,792
New +$1.17M 0.06% 29
2020
Q1 		– Sell
-2,649
Closed -$230K – 35
2019
Q4 		$230K Buy
2,649
+7
+0.3% +$575 0.01% 28
2019
Q3 		$212K Buy
2,642
+8
+0.3% +$641 0.01% 29
2019
Q2 		$211K Buy
2,634
+8
+0.3% +$613 0.01% 28
2019
Q1 		$208K Buy
2,626
+8
+0.3% +$598 0.01% 28
2018
Q4 		$191K Buy
2,618
+7
+0.3% +$494 0.01% 29
2018
Q3 		$177K Sell
2,611
-7,587
-74% -$483K 0.01% 27
2018
Q2 		$590K Buy
10,198
+9
+0.1% +$508 0.03% 25
2018
Q1 		$529K Buy
10,189
+10
+0.1% +$540 0.03% 25
2017
Q4 		$547K Buy
10,179
+378
+4% +$21K 0.03% 25
2017
Q3 		$599K Buy
9,801
+8
+0.1% +$485 0.03% 24
2017
Q2 		$599K Buy
9,793
+9
+0.1% +$548 0.05% 20
2017
Q1 		$593K Sell
9,784
-1,323,656
-99% -$80.3M 0.05% 21
2016
Q4 		$74.9M Sell
1,333,440
-237,288
-15% -$13.9M 6.04% 10
2016
Q3 		$93.5M Sell
1,570,728
-25,384
-2% -$1.48M 6.48% 10
2016
Q2 		$87.7M Sell
1,596,112
-56,061
-3% -$2.98M 6.72% 10
2016
Q1 		$83.4M Buy
1,652,173
+488,973
+42% +$23.9M 6.65% 9
2015
Q4 		$58.6M Sell
1,163,200
-8,066
-0.7% -$407K 5.87% 10
2015
Q3 		$55.2M Sell
1,171,266
-24,428
-2% -$1.3M 6.05% 9
2015
Q2 		$65M Sell
1,195,694
-11,553
-1% -$648K 8.11% 8
2015
Q1 		$66.2M Sell
1,207,247
-2,338
-0.2% -$132K 8.05% 9
2014
Q4 		$65.5M Buy
1,209,585
+87,791
+8% +$4.89M 8.61% 7
2014
Q3 		$63.5M Buy
1,121,794
+61,673
+6% +$3.46M 9.47% 5
2014
Q2 		$58.5M Sell
1,060,121
-17,456
-2% -$952K 8.95% 7
2014
Q1 		$58.4M Buy
1,077,577
+41,977
+4% +$2.17M 9.72% 5
2013
Q4 		$49.5M Buy
1,035,600
+138,275
+15% +$6.32M 9.98% 5
2013
Q3 		$40.8M Buy
897,325
+135,045
+18% +$6.17M 9.49% 4
2013
Q2 		$33.8M Buy
+762,280
New +$34M 7.68% 7

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACR Alpine Capital Research's MRK Position: Q1 2026 in Review

ACR Alpine Capital Research increased its Merck (MRK) stake by 6.9% in Q1 2026, buying an estimated $295K and bringing the position to 39,449 shares worth $4.75M. The position accounts for 0.07% of the portfolio, ranked #26.

ACR Alpine Capital Research first reported a position in MRK in Q2 2013 and has held it in 44 quarters since. The position peaked at $93.5M in Q3 2016. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • ACR Alpine Capital Research held 39,449 shares of Merck worth $4.75M as of Q1 2026.
  • ACR Alpine Capital Research bought 2,553 Merck shares in Q1 2026, an estimated $295K.
  • Merck made up 0.07% of ACR Alpine Capital Research's portfolio in Q1 2026, its #26 holding.
  • ACR Alpine Capital Research first reported a position in Merck in Q2 2013 and has held it in 44 quarters since.
  • ACR Alpine Capital Research's Merck position peaked at $93.5M in Q3 2016.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on ACR Alpine Capital Research's 13F filing for Q1 2026, filed 30 Apr 2026.